Novosom Licenses Next-Generation CD40 Targets From Isis
This article was originally published in The Pink Sheet Daily
Novosom plans to use Isis’ antisense oligonucleotides targeting CD40 with its proprietary Smarticles technology to enhance delivery.
You may also be interested in...
Firms confident, but some analysts skeptical about what might be required for approval of lipid antisense drug.
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.